---
title: "华润医药旗下哮喘吸入粉雾剂获 FDA 批上市"
description: "华润医药公布，集团旗下润生药业提交的沙美特罗替卡松吸入粉雾剂获得美国食品药品监督管理局 (FDA) 上市批准，是 FDA 首次批准来自中国药企自主研发的吸入粉雾剂。沙美特罗替卡松吸入粉雾剂以联合用药形式 (支气管扩张剂与吸入糖皮质激素)，用于可逆的气道阻塞性气道疾病的规律治疗，包括成人和儿童哮喘。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/272792273.md"
published_at: "2026-01-16T06:13:29.000Z"
---

# 华润医药旗下哮喘吸入粉雾剂获 FDA 批上市

> 华润医药公布，集团旗下润生药业提交的沙美特罗替卡松吸入粉雾剂获得美国食品药品监督管理局 (FDA) 上市批准，是 FDA 首次批准来自中国药企自主研发的吸入粉雾剂。沙美特罗替卡松吸入粉雾剂以联合用药形式 (支气管扩张剂与吸入糖皮质激素)，用于可逆的气道阻塞性气道疾病的规律治疗，包括成人和儿童哮喘。

华润医药 (03320.HK) 公布，集团旗下润生药业提交的沙美特罗替卡松吸入粉雾剂获得美国食品药品监督管理局 (FDA) 上市批准，是 FDA 首次批准来自中国药企自主研发的吸入粉雾剂。

沙美特罗替卡松吸入粉雾剂以联合用药形式 (支气管扩张剂与吸入糖皮质激素)，用於可逆的气道阻塞性气道疾病的规律治疗，包括成人和儿童哮喘。

### Related Stocks

- [03320.HK - 华润医药](https://longbridge.com/zh-CN/quote/03320.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 10:31 ETRespiratory Care Devices Market to Reach $47.9 billion, Globally, by 2033 at 7.6% CAGR: Allied Market Research | The global respiratory care devices market is projected to grow from $22.9 billion in 2023 to $47.9 billion by 2033, at  | [Link](https://longbridge.com/zh-CN/news/275778433.md) |
| Anta Sports Products gets written shareholders' approvals from Anta International, units | Anta Sports Products gets written shareholders' approvals from Anta International, units | [Link](https://longbridge.com/zh-CN/news/275885036.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/zh-CN/news/275851575.md) |
| A sexually transmitted ringworm is spreading in one US state | Minnesota is experiencing the largest outbreak of sexually transmitted ringworm (TMVII) in the U.S., with over 30 confir | [Link](https://longbridge.com/zh-CN/news/275977276.md) |
| BUZZ-Upstream Bio jumps as experimental asthma drug shows promise in mid‑stage study | Shares of Upstream Biosurged 20% to $32.64 in premarket trading following positive results from a mid-stage study of its | [Link](https://longbridge.com/zh-CN/news/275596211.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。